Galectin Therapeutic (GALT) Stock Price, Quote & News

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 620 3186

Website: galectintherapeutics.com

Address:

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

JollyAcorn2021 Nov. 15 at 12:58 PM

$GALT “Right now, wether you know it or not, there is a fight happening for the last 25% of the fully diluted stock that we as retail currently hold. Know what you own. “ - from the below post. As somebody else on this board noted: the share price fuckery we will probably see as they try to get our shares will be mind blowing!

0 · Reply

fluffball Nov. 15 at 11:38 AM

$GALT my guess is that they applied for breakthrough status from the FDA in mid Oct, at the same time as they announce their participation to AASLD. That would fit the timetable of FDA response within the 60days after submissions and disclosure to the public 4 days after the announcement. Would perfectly align to their end of year news from the FDA. Just my 2 cents.

3 · Reply

LiquidThetaOptions Nov. 15 at 9:17 AM

💎 LiquidTheta® Live Actionable Trade Asset: $GALT Contracts: $GALT January 15, 2027 $8 Calls Scale in: $1.69- $2.06 Scale out: $6.56-$11.25 Profit Potential : 200% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

th3_fail_k1ng Nov. 15 at 8:53 AM

$GALT @Boellie my two bits, we have been speculating we were in a quiet period since August. This is a 10b pre-planned sale. All three of them, Joel, Jim and now Jamil were firing from the hip months ago trying to hit the future bo announcement in the dark before negotiations actually started. Jamil got closest so far and he seemed to target right after the aasld liver meeting presentation and earnings. This tells us, imo, insiders have all been expecting a material event that will prohibit the trading if their shares around this time......

1 · Reply

Boellie Nov. 15 at 5:47 AM

$GALT what about the last form 4… doctor Jamil?

2 · Reply

ThomasLD Nov. 15 at 4:44 AM

$AUPH $GALT “Chaotic winter night”, “cold snowy day” 🎶 Have a wonderful weekend! Your wonderful Christmas 🎄 is coming soon! https://youtu.be/zXdjyO9eVjk

0 · Reply

MoneyGroupLLC Nov. 15 at 3:12 AM

Enter: $GALT Calls Strike Price: $8 Expiry Date: DEC 19 2025 Buy in Price: $0.40 - $0.75 Sell Price: $0.64 Profit : +60% (Turn every $1 into $1.60) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

ThomasLD Nov. 15 at 2:14 AM

$GALT Basically the company is very confident with the data and expect to hear back from FDA within a month with a new voucher program.

1 · Reply

th3_fail_k1ng Nov. 15 at 2:02 AM

$GALT First @Kilarck found this and here's why it's important Sections 6 and 7 of the current 10Q show that all outstanding unexercised warrants held by 10x fund have been canceled. It is a standard M&A practice that the purchasing company requires in the money warrants to be exercised or canceled prior to the announcement of a buyout. 10x's warrants required 30 days notice to be canceled. @Kungfujones told us early October that all 10x fund members had received a formal communication from the company saying that if they intended to exercise their warrants they needed to do so and the company felt it would be in their best interest to do so by October 11th. and now the remaining warrants that weren't converted have been canceled. This is a huge merger acquisition signal, expect the bo and FDA feedback announcements to be released in the same PR Wow I guess this is a benefit of having a world-renowned expert in economic warfare on your board of directors, right? TICK TOCK SHORTY

5 · Reply

gscdefense Nov. 15 at 1:30 AM

$GALT I know this is a house of learned doctors but good lord this is all coming to fruition so fast.

1 · Reply

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Sep 2, 2025, 8:00 AM EDT - 2 months ago

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

May 12, 2025, 8:00 AM EDT - 6 months ago

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Mar 31, 2025, 8:00 AM EDT - 8 months ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Jan 10, 2025, 8:00 AM EST - 11 months ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Dec 20, 2024, 10:29 AM EST - 11 months ago

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Dec 20, 2024, 8:00 AM EST - 11 months ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Nov 18, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

May 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 20, 2024, 8:11 PM EDT - 1 year ago

Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Dec 7, 2023, 6:00 AM EST - 2 years ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Nov 13, 2023, 8:45 AM EST - 2 years ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GLTO

Sep 13, 2023, 5:22 PM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 7, 2023, 12:00 PM EDT - 2 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

May 15, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

Apr 27, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Mar 30, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 24, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 5, 2023, 8:00 AM EST - 3 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Nov 28, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 14, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 1, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Aug 15, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Jul 26, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

Jul 11, 2022, 4:16 PM EDT - 3 years ago

Galectin: Ability To Potentially Target Unmet Medical Need

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

May 23, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

May 16, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

Apr 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

JollyAcorn2021 Nov. 15 at 12:58 PM

0 · Reply

fluffball Nov. 15 at 11:38 AM

3 · Reply

LiquidThetaOptions Nov. 15 at 9:17 AM

0 · Reply

th3_fail_k1ng Nov. 15 at 8:53 AM

1 · Reply

Boellie Nov. 15 at 5:47 AM

$GALT what about the last form 4… doctor Jamil?

2 · Reply

ThomasLD Nov. 15 at 4:44 AM

$AUPH $GALT “Chaotic winter night”, “cold snowy day” 🎶 Have a wonderful weekend! Your wonderful Christmas 🎄 is coming soon! https://youtu.be/zXdjyO9eVjk

0 · Reply

MoneyGroupLLC Nov. 15 at 3:12 AM

0 · Reply

ThomasLD Nov. 15 at 2:14 AM

$GALT Basically the company is very confident with the data and expect to hear back from FDA within a month with a new voucher program.

1 · Reply

th3_fail_k1ng Nov. 15 at 2:02 AM

5 · Reply

gscdefense Nov. 15 at 1:30 AM

$GALT I know this is a house of learned doctors but good lord this is all coming to fruition so fast.

1 · Reply

History101 Nov. 14 at 11:36 PM

$GALT

0 · Reply

johnhankowitz Nov. 14 at 11:19 PM

$GALT Nice churning, accumulation & consolidation this week. Have a great weekend my fellow longs. I’m thinking $6+ BREAK coming next week…GL

1 · Reply

geronimlopez Nov. 14 at 10:53 PM

$GALT Good trading action this week, looks like it might be coiling up to move above 6 next week!

0 · Reply

Schuuultz Nov. 14 at 10:13 PM

$GALT @squiggleburp , your problem may be that you TRADED it poorly instead of buying and holding. You still have time to make things right...a few seconds or so, IMO.

1 · Reply

ThomasLD Nov. 14 at 9:55 PM

$GALT @th3_fail_k1ng @drewski1515 Here you go!

0 · Reply

th3_fail_k1ng Nov. 14 at 9:27 PM

$GALT of the CURRENTLY availabile shares about half are now held by tutes and insiders However, and this is where it gets interesting..... Fully Diluted on a buyout announcement: 70ish% will be held by insiders (the dilution is Uhlines credit lines and 4 million retail warrants with a 7 strike price) and insiders will be locked out from trading 6ish%n(as it stands now) will be held by tutes Right now, wether you know it or not, there is a fight happening for the last 25% of the fully diluted stock that we as retail currently hold. Know what you own.

4 · Reply

2TrustHim Nov. 14 at 9:20 PM

$GALT $662,510 Must Be Holiday Money!!!

1 · Reply

2TrustHim Nov. 14 at 9:08 PM

$GALT http://archive.fast-edgar.com/20251114/AQ2A422CZ22282Z2222B22YYI5V3Z3223272

1 · Reply

Indibviduate1 Nov. 14 at 9:06 PM

$GALT the drug works. The only drug that works for these patients.

0 · Reply

th3_fail_k1ng Nov. 14 at 9:06 PM

$GALT like I said regulation tutes can only buy shares if you are willing to sell them. Rest assured the WANT THEM.

2 · Reply

Willie3000 Nov. 14 at 8:34 PM

$GALT ADDED. NFA.... 😎🤙📈🚀

0 · Reply

Glowbutt303 Nov. 14 at 8:31 PM

$GALT you should read todays press release! This management team rarely speaks this way……https://investor.galectintherapeutics.com/news-releases/news-release-details/galectin-therapeutics-reports-financial-results-quarter-ended-15

0 · Reply

Market Cap	356.57M
Revenue (ttm)	0.00
Net Income (ttm)	-47.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	238,800
Avg Vol	368,240
Day's Range	N/A - N/A
Shares Out	64.48M
Stochastic %K	38%
Beta	0.86
Analysts	Sell
Price Target	$6.00